Mechanism of immunomodulatory drugs in multiple myeloma

Lenka Sedlarikova; Lenka Kubiczkova; Sabina Sevcikova; Roman Hajek

doi:10.1016/j.leukres.2012.05.010

Mechanism of immunomodulatory drugs in multiple myeloma

Leuk Res. 2012 Oct;36(10):1218-24. doi: 10.1016/j.leukres.2012.05.010. Epub 2012 Jun 21.

Authors

Lenka Sedlarikova¹, Lenka Kubiczkova, Sabina Sevcikova, Roman Hajek

Affiliation

¹ Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

PMID: 22727252
DOI: 10.1016/j.leukres.2012.05.010

Abstract

Multiple myeloma is the second most common hematological cancer in the world. It is characterized by accumulation of malignant plasma cells in the bone marrow, osteolytic lesions and monoclonal immunoglobulins in blood/urine. With the introduction of immunomodulatory drugs into the treatment protocol, the outcome of multiple myeloma patients has dramatically improved with more than 30% of patients surviving for 10 years thus shifting multiple myeloma to a treatable condition.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Humans
Immunologic Factors / therapeutic use*
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology*

Substances

Immunologic Factors